So says The Washington Post. I’ve been writing about gray-market peptides in Optimizer, but this is a follow-up to July’s FDA hearings about whether compounding pharmacies should be allowed to sell unapproved peptides. It’s unclear which ones, and the timing could change, but the Post says this might give the administration a “political upside.”